Case Study: a private gene therapy company defines its path-to-market strategy with Certara

Defining path-to-market strategy through a data-driven and scientific approach

Certara was approached by a private gene therapy company specializing in RNA carriers that had not yet identified which therapeutic indications to target with its licensed lentiviral vector technology. The client's challenge was to define a strategic and de-risked path to market for its promising but untargeted technology.

Certara implemented a multi-step, data-driven research approach to systematically narrow down over 200 potential indications to a refined shortlist. The solution involved assessing each indication on criteria like unmet need and competitive intensity, ultimately selecting top "gateway" and "value" indications and creating Target Product Profiles for each. As a result, Certara provided the client with a reliable framework for their clinical strategy, which they used as a foundation to successfully recruit clinicians and advance their promising technology toward the market.